Publication

• Strategies for developing selective p21-activated kinase (PAK) Inhibitors.
• J.H. Kim, S. Lee*
• Yakhak Hoeji. 2025, 69(4), 328.
• 
  
• Pharmacological profiles of Gynostemma Pentaphyllum: A therapeutic candidate from Jeju.
• C.H. Kwon, H. Choi, S. Lee*, M.W. Ha*
• Jeju J. Island Sci. 2025, 2(2), 50.
• 
  
• Recent Advances in Visible Light-Driven Multicomponent Reactions of Aryl Diazonium Tetrafluoroborates.
• T.G. Luu, S. Lee, H.-K. Kim*
• Eur. J. Org. Chem. 2025, 28, e202401440.
• 
  
• Structural modification of C2-substituents on 1,4 bis(arylsulfonamido)benzene or naphthalene- N,N′-diacetic acid derivatives as potent inhibitors of the Keap1-Nrf2 protein-protein interaction.
• S. Lee, A. R. Ali, D. A. Abed, L. M.-U. Nguyen, M. P. Verzi, L. Hu*
• Eur. J. Med. Chem. 2024, 265, 116104.
  
• 
  
• Optimization of the C2 substituents on the 1,4 bis(arylsulfonamido)naphthalene-N,N′-diacetic acid scaffold for better inhibition of Keap1-Nrf2 protein-protein interaction.
• D. A. Abed§, A. R. Ali§, S. Lee, L. M.-U. Nguyen, M. P. Verzi, L. Hu
• Eur. J. Med. Chem. 2023, 252, 115302.
• 
  
• Structure-activity relationships of 1,4-bis(arylsulfonamido) benzene or naphthalene-N,N’-diacetic acids with varying C2-substituents as inhibitors of Keap1-Nrf2 protein-protein interaction.
• S. Lee, D. A. Abed, L. M.-U. Nguyen, M. P. Verzi, L. Hu*
• Eur. J. Med. Chem. 2022, 237, 114380.
• 
  
• Optimization of 1,4- bis(arylsulfonamido)naphthalene-N,N’-diacetic acids as inhibitors of Keap1-Nrf2 protein-protein interaction to suppress neuroinflammation.
• D. A. Abed§, S. Lee§, X. Wen, A. R. Ali, V. Mangipudy, L. M. Aleksunes, L. Hu*
• Bioorg. Med. Chem. 2021, 44, 116300.
• 
  
• Design, synthesis, and biological evaluation of potent 1,2,3,4-tetrahydroisoquinoline derivatives as anticancer agents targeting NF-κB signaling pathway.
• S. Si§, S. Lee§, S. Ko, B. P. Bui, P. L. Nguyen, J. Cho, K. Lee, J.-S. Kang, J.-K. Jung, H. Lee*
• Bioorg. Med. Chem. 2021, 46, 116371.
• 
  
• Development of a homogeneous time-resolved fluorescence energy transfer (TR-FRET) assay for the inhibition of Keap1-Nrf2 protein-protein interaction.
• S. Lee, D. A. Abed, L. J. Beamer, L. Hu*
• SLAS Discov. 2021, 26(1), 100-112.
  
• 
  
• Discovery of thienothiazolocarboxamide analogues as novel anti-tubercular agent.
• G. Jin, Y. M. Kim, A. Lee, J. Choi, S. Kang, M. Seo, J. J. Seo, S. Lee, J. Kang, J. Kim, S. Park, M.    Woo, V. Carla, H. Lee, J. Heo, D. Shum, K. Park, V. Delorme, I. Choi*
• Bioorg. Med. Chem. 2020, 28(23), 115797.
• 
  
• Nrf2 activation through the inhibition of Keap1-Nrf2 protein-protein interaction.
• S. Lee, L. Hu*
• Med. Chem. Res. 2020, 29(5), 846-867.
• 
  
• Discovery of disubstituted xylylene derivatives as small molecule direct inhibitors of Keap1-Nrf2 protein-protein interaction.
• D. A. Abed, S. Lee, L. Hu*
• Bioorg. Med. Chem. 2020, 28(6), 115343.
• 
  
• Design, synthesis, and evaluation of L-cystine diamides as L-cystine crystallization inhibitors for cystinuria.
• Y. Yang, H. Albanyan, S. Lee, H. Aloysius, J.-J, Liang, V. Kholodovych, A. Sahota, L. Hu*
• Bioorg. Med. Chem. Lett. 2018, 28, 1303-1308.
• 
  
• Jew Novel   CinchonaAminobenzimidazole Bifunctional Organocatalysts.
• L. Zhang, M.-M. Lee, S.-M. Lee, J. Lee, M. Cheng, B.-S. Jeong, H.-G. Park, S.-S.*
• Adv. Synth. Catal. 2009, 351, 3063-3066.

Anti-infective compounds

Institut Pasteur Korea

• 2025, United States Patent US12227524B2 (등록)

• 2023, South Korea Patent KR102582563B1 (등록)

• 2022, United States Patent US11279714B2 (등록)

• 2021, Russia Patent RU2753403C2 (등록)

• 2020, European Patent EP3157904B1 (등록)

• 2020, China Patent CN107027307B (등록)

• 2015, PCT International Application PCT/EP2015/063982 (출원)

E3 리가제 리간드 화합물, ALK 및/또는 EGFR 돌연변이 키나제 억제 효과를 나타내는 화합물 및 이의 의약 용도

J2H Biotech

• 2024, Korea Patent 1020240016825 (출원)

ALK 및/또는 EGFR 돌연변이 키나제 억제 효과를 나타내는 화합물 및 이의 의약 용도

J2H Biotech

• 2024, Korea Patent KR1026851870000 (등록)

• 2023, PCT International Application 1026851870000 (출원)

Anti-infective compounds

Institut Pasteur Korea, Qurient Co Ltd

• 2021, Spain Patent ES2883565T3 (등록)

• 2021, European Patent EP3027615B1 (등록)

• 2021, South Korea Patent KR102292293B1 (등록)

• 2021, Denmark Patent DK3027615T3 (등록)

• 2020, Russia Patent RU2734760C2 (등록)

• 2020, Japan Patent JP6757768B2 (등록)

• 2014, PCT International Application PCT/EP2014/066614 (출원)

Compounds for treatment of inflammatory diseases.

Institut Pasteur Korea, Qurient Co Ltd

• 2017 Korea Patent KR101715449B1 (등록)

Compounds for treatment of inflammatory diseases.

Institut Pasteur Korea, Qurient Co Ltd

• 2017 Korea Patent KR101715448B1 (등록)

Compounds for treatment of inflammatory diseases.

Institut Pasteur Korea, Qurient Co Ltd

• 2016 Korea Patent KR101646833B1 (등록)

Pharmaceutical compound for treatment of inflammatory diseases.

Institut Pasteur Korea, Qurient Co Ltd

• 2015 Korea Patent KR101503647B1 (등록)

A compound and a pharmaceutical compound for treatment of inflammatory diseases.

Institut Pasteur Korea, Qurient Co Ltd

• 2015 Korea Patent KR101496094B1 (등록)

A compound and a pharmaceutical compound for treatment of inflammatory diseases.

Institut Pasteur Korea, Qurient Co Ltd

• 2015 Korea Patent KR101496095B1 (등록)

A compound and a pharmaceutical compound for treatment of inflammatory diseases.

Institut Pasteur Korea, Qurient Co Ltd

• 2015 Korea Patent KR101480674B1 (등록)